BRONCHODILATORS → LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) → Spiriva® Respimat®

Spiriva® Respimat®

BRONCHODILATORS

LONG-ACTING MUSCARINIC ANTAGONIST (LAMA)

  • Class

    • Long-acting muscarinic antagonist (LAMA)

  • Active ingredient

    • Tiotropium (as bromide)

  • Device

  • Age

    • 18 +

  • Typical use

    • Asthma
      in addition to a high dose ICS + LABA when uncontrolled

    Asthma management principles

    • COPD
      initial treatment or in addition to a LABA when uncontrolled

    COPD management principles

  • Marketed strength

    • 2.5 mcg

  • Number of doses

    • 60 doses

  • Dose indicator

    • Yes | Indicator

  • Usual adult dosage

    • 2 inh QD

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • < 30 L/min
      Zero internal resistance (R0)

    Inspiratory flows

  • Public coverage

    • AB – BC – MN – NIHB – ON – QC – SK – YT | Open/Regular Benefit
      NB – NL – NS – PEI | Restricted Benefit with criteria 

    Provincial coverage criteria

  • Advantages

    • Suitable for low inspiratory flows
    • Impossible to take empty (locking mechanism)
    • Can be used with a spacer
    • No taste

  • Disadvantages

    • Cartridge insertion difficult
    • Base turn for loading difficult
    • Risk of spraying the face if cap opened before rotating the base
    • Occasional cough without spacer
    • Synchronism required
    Side effects

Product monograph

Download

Tudorza®

Genuair®

Seebri®

Breezhaler®

Spiriva®

Handihaler®

Incruse®

Ellipta®

Search for other inhalers

Explore the full list